Published in Journal of Neurotrauma · View the paper (DOI)
Researchers developed a point-of-care GFAP assay that delivers results in minutes, outperforming the current FDA-cleared assay. The assay's diagnostic performance was significantly better than that of the S100B biomarker, validating its utility as a diagnostic marker for CT-detected lesions.
Coverage from 2 institutions
- Point-of-care biomarker assay for traumatic brain injury Mary Ann Liebert, Inc./Genetic Engineering News · Sep 16, 2020 · first to report
- Rapid blood test could detect brain injury in minutes, study shows University of Pittsburgh · Sep 17, 2020